Answers are grounded in this paper and cite their sources.
The focus of drug development has moved from cytotoxic compounds identified by screening to therapies that act at specific molecular targets. Although some of these agents may cause visible tumor reduction and may be adequately evaluated by standard oncology drug development methods, other novel therapies may not be amenable to our current practices. Consequently, our concepts of drug development must evolve and address various questions. How should we approach the preclinical development of these agents? Which laboratory experiments are critical prior to studying these new agents in the clinic? What phase I design strategies are appropriate? Agents that target specific molecules may not cause toxicity at effective doses and, therefore, phase I concepts such as maximum tolerated dose (MTD) may not be relevant. What phase II designs suit these agents? Drugs that have a cytostatic effect may be overlooked if tumor response is required as a selection criteria. Phase II studies may not be necessary if the relevant end point is survival, which cannot be fully addressed without a large randomized phase III trial. What can we learn from other areas of medicine? Many nononcology drugs target specific end points and are developed in a pattern quite different from the formula used in oncology. Should we be adopting their methods of drug development? At the 10th National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer Therapy, a workshop discussed these issues. In this commentary, we summarize some of the presentations. Although many new agents are entering or are already in clinical trials, it is imperative that we continue this dialogue with scientists, clinical researchers, cooperative groups, and industry and regulatory authorities because there is not yet an international consensus on how to approach the challenges that lie ahead. The current era of anticancer drug discovery and development is based on the concept that, by identifying small molecules and genes targeting the precise molecular abnormalities that create and drive the malignant phenotype ( 1 ), therapies will emerge that are both more effective and better tolerated than the traditional cytotoxic agents ( 2 , 3 ). Examples of molecularly targeted signal transduction agents include inhibitors of ras farnesylation and receptor kinase inhibitors. Approaches that target the tumor cell environment include metalloprotease and integrin inhibitors as well as antiangiogenic strategies. Such agents present a major challenge to the process of preclinical assessment. Preclinical studies must demonstrate that a candidate agent selected for clinical development acts by the desired molecular mechanism (e.g., inhibition of a specific receptor tyrosine) and thereby produces the desired biologic effect (e.g., inhibition of proliferation or the induction of apoptosis). The agent must also exhibit in vivo antitumor activity and a suitable therapeutic index (i.e., ratio of the dose that brings about an anticancer effect to the dose that brings about a toxic effect). Traditional end points, such as simple tumor cell killing or growth delay, are not by themselves sufficient for this contemporary need. The opportunity presented is to replace such blunt instruments with more specific end points that are tailor-made for any particular molecular target. Mechanism-based approaches require corresponding mechanism-based end points. Replacing “black box” approaches with tailor-made assessments means that the process of anticancer drug discovery and development becomes less routine and places greater demands on the biologists and pharmacologists involved. In addition, there is pressure both in terms of unmet medical need and commercial concerns to deliver candidates for clinical development faster than ever before ( 4 ). Companies that have already adopted aggressive time scales of 5-7 years from a potential new target to a development candidate are now seeking to shorten these still further. Faster development can be achieved only by exploiting the latest technologic advances, many of which are in their infancy and rapidly changing ( 5 ). These technologies involve 1) methods developed for modern molecular biology and genomics/proteomics to identify and validate new therapeutic targets, 2) robotic high-throughput screening against structurally diverse chemical libraries to discover lead drugs ( 6 , 7 ), 3) combinatorial chemistry for the efficient generation of structural diversity and for rapid production of a library of structural analogues based on an identified lead compound (known as lead explosion) and optimization ( 8 , 9 ), 4) enhanced structural biology and molecular modeling techniques for rational drug design ( 10 ), 5) high-throughput pharmacokinetics assays ( 11 ), and 6) the use of surrogate end points to monitor pharmacodynamics throughout the discovery and development process, particularly involving genomics (e.g., nucleic acid microassays) and proteomics ( 12 ). Bottlenecks exist. In particular, bottlenecks occur with respect to understanding the biologic function of genes discovered through genomic approaches, the validation of potential drug targets, conversion of lead drugs active in vitro into agents with drug-like properties and pharmacologic activity in the intact animal, and the establishment of appropriate assays to measure specific molecular mechanisms and biologic effects. Therefore, these are the areas that require the greatest attention in terms of technology development at the present time. Whether a drug discovery program is based on screening, a structure-based approach, or some combination of these approaches, a robust, efficient, and informative test cascade is essential ( 13 ). This should be based on a target profile that defines the essential and desirable properties of the molecule sought (e.g., in terms of potency, selectivity, pharmacokinetics, and therapeutic index). A typical contemporary test cascade consists of a series of hierarchical assays. These assays usually begin with an initial biochemical assay on the recombinant target protein and proceed to in vitro cell tests and in vivo evaluation of pharmacokinetic and pharmacodynamic behavior to a final cancer disease model such as a human tumor xenograft (Fig. 1) . When interesting agents are discovered because of a unique cellular fingerprint or because of an association with molecular target expression, as in the National Cancer Institute's tumor panel ( 14 ), specific assays must also be applied to confirm the mode of action and optimize the lead drug. Examples of the mode-of-action assays include analysis of the changes in phosphorylation of a particular target protein, the disruption of a protein-protein interaction, or the disruption of an appropriately engineered reporter gene system. A frequent point of failure in drug discovery programs is poor pharmacokinetic behavior when the agent progresses from testing in cell culture to testing in the intact animal ( 15 ). Therefore, it is essential that these agents possess robust, “drug-like” properties (absorption, distribution, metabolism, and excretion) and the potential for sustained administration (e.g., for signal transduction inhibitors). This issue is being addressed by determining approximate pharmacokinetic properties of drug leads by the cocktail or cassette dosing approach that involves administering compounds at low doses in mixtures, followed by high-sensitivity high-performance liquid chromatography-mass to charge ratio-mass spectroscopy analysis ( 16 ). For initial pharmacodynamic end points, the hollow fiber tumor assay provides an “ in vitro-in vivo hybrid” to bridge the divide between cell culture and animal experiments ( 17 ). Surrogate markers of mode of action or biologic effect can be used alongside or instead of the hollow-fiber test. For example, an anti-inflammatory assay could be used to measure effective blockade of the phosphatidylinositol 3-kinase pathway. The use of such pharmacokinetic and surrogate pharmacodynamic end points provides the advantages of rapid and potentially cost-effective turnaround of in vivo results and a less demanding hurdle during the in vivo lead optimization phase compared with a full-blown disease model. However, suitably optimized compounds will normally require testing in a more challenging biologic system. Human tumor xenografts are often used for this purpose ( 18 ), but these models can be criticized as poorly predictive of the human disease (although it is, in fact, too early to judge this for the newer molecular targets) ( 19 ). These concerns may be especially relevant where the drug effect sought inhibits angiogenesis or metastasis. A case can be made for the construction and use of more complex disease models, such as orthotopic systems ( 20 ) or transgenic animals ( 21 ), as was done for evaluating ras farnesylation inhibitors ( 22 ). In some cases, well-characterized syngeneic models may have advantages over human tumor xenografts. It should be remembered that regressions might not be seen with signal transduction or cell cycle inhibitors, unless of course the agent induces apoptosis. In all situations, a decision to proceed to the clinic will require some evidence of activity in an in vivo disease model such as a human tumor xenograft. However, where there are real concerns about the clinical relevance of such models, a more controversial position is to look predominantly for evidence of “hitting the target” in preclinical in vivo models and to carry out the critical clinical hypothesis test in humans. Toxicologic evaluation is essential to ensure acceptable safety, to identify organs at risk, and to determine a safe phase I starting dose. However, because excessive preclinical evaluation can cause delay and is often poorly predictive, organizations such as the Cancer Research Organization and the European Organization for Research and Treatment of Cancer favor entering clinical trials after a relatively simple program of rodent-only toxicology testing ( 23 , 24 ). There are major advantages to be gained if the mode of action and surrogate assays, ideally measuring biochemical effects as close as possible to the precise molecular locus, are capable of translation for use in the early clinical studies because they smooth the transition from preclinical assessment to human investigation. In this regard, noninvasive assays, such as magnetic resonance spectroscopy, magnetic resonance imaging (MRI), and positron emission tomography (PET), are especially attractive ( 25 ). Phase I trial design should incorporate the evaluation of safety and toxicity with a measure of the outcome at the molecular level. The ideal situation for proceeding from the laboratory to a clinical trial after a validated target effect is something that must be coordinated between the laboratory scientists and the clinical researchers before the initiation of the clinical program (Table 1) . As described above, a comprehensive preclinical package is necessary, target that the response by and for target inhibition or in or phase I designs ( ) are used for drugs that have cytotoxic and there is a of clinical to this However, novel agents (e.g., inhibitors of protein kinase and growth receptor have a therapeutic and an may be or to Drugs on specific that may be or in cancer may in low therefore, a dose to may be an end preclinical results can an end such as the of the drug corresponding to in to the it may be to the dose followed by the dose in of the that inhibits the response by It may also be to the of drug required to the target and to use that dose in trials (i.e., phase without to Phase I design may require dosing or the of to different dose with doses from the preclinical studies and based on the dose required to the target. The end point in phase I trials for targeted therapies should evolve from the current of a in to a more suitable end point of the dose required to the relevant target. this cannot be all studies will be out clinical researchers that a dose is being used when and toxicity in are molecularly targeted these end points may not be unless there are markers of target activity that are or this is not necessary if occur in phase as with the the of protein kinase ( ), and this is relevant for drugs that not a response (e.g., metalloprotease inhibitors). In some of these trials, the of of the relevant markers has used as the end point ( 1 ). The may not be target inhibition but target strategies have developed to approach the of measuring target These begin to with the current of a phase II trial. approach be the administration of drug and analysis of the drug and target activity in the Many tumor are with for these cases, a with is that or that of could be The for a and a of target activity the time to trials and the all trials and drug development from the that the dose was and the target for which it was standard may need to be with more of based on molecular Phase II trials of targeted may not use but may with from different that molecular markers (e.g., or gene There are many challenges to tumor analysis into the design of a clinical trial. these challenges the of human and and of to ensure that the tumor is being other less approaches can be The approach which possess many and relevant to novel a effective in can the design of dose This dose is not a because it is not the need to the tumor target in studies but is an pharmacodynamic measure of biologic have with a of and include inhibition of phosphorylation ( ), inhibition of tumor ( ), of 6 ( ), and of tumor by protein kinase inhibitors ( ). In some where of the target is in these not to proceed with testing of the agent may be made without tumor The approach newer imaging and can measure metabolism, and ( ). drugs can of the drug achieved at tumor can also ( ) and particularly applied to cancer to Many newer agents or tumor angiogenesis ( ), therefore, inhibition of angiogenesis is a biologic end These need to be for and which should occur in with the clinical studies (e.g., of of these techniques the end of phase I should continue into phase II to assessment of of or must be and these may require novel pharmacokinetic modeling and such as of drug may be more relevant than and may not be Preclinical models that many of the novel agents may tumor growth than tumor This outcome may be to and may be when applied to at dosing may be necessary to and or many in phase I trials for only a often only 1 or 2 the required for evidence of biologic activity and phase II dosing may not be from the initial dose and to phase II should be in the trial design that can be for a It is not molecularly targeted therapies will be active with cytotoxic or with other targeted of these cannot be fully with the current preclinical and phase I design without the well into the between laboratory researchers and clinical is necessary to design of tests that will early clinical trials of these based on preclinical results of preclinical studies have some of our current clinical as acid and and may be a model for that may not be a that or more agents may be desirable and may the initiation of early trials without the in the use of a of therapies by different phase I trials are the of clinical is to as and as possible the of the new agent in a of in this is as survival, or of phase II trials have used to new agents for evidence of biologic activity in of before proceeding into large phase III trials in which may be tumor as a in the of the the and the corresponding that is in a of has to be a for or agents for Although not all of the agents that are selected on the of response results in phase II trials have to survival, sufficient have done to validate response as a phase II end of tumor growth than tumor is the clinical screening agents for with standard phase II response end points may be approaches are 1) to identify surrogate end points for in phase II tumor response or 2) to the new agent from phase I into randomized There has in the of these the of end points to response that may be used to appropriately or a new drug in a phase II However, it is to that any end point must be as being only response has used to identify agents that have an on candidate end points are as time to changes in tumor of target of with early disease and assessment of clinical Although time to disease has the of being a and end point in randomized trials, it is to when there is and when are as is the case in a phase II markers also the of being well described and The with markers as an end point to active agents is that the use of markers to identify active agents has ( ) that, in the tumor may for the of response in phase II trials, but these in where the drugs also tumor For cytostatic agents in it is not a tumor will with and, if it the agent can still cause tumor ( ) has that a in the of in a relevant may be a end point for identifying an active In studies of a to a in the of of the tumor an effect that also to demonstrate a trials based on these are proceeding for with and and the results of these studies may to validation of this end before a tumor is as a surrogate for drug it must be that the drug cannot of the through changes to tumor Such a be the of the from the which has for some agents ( ). of target inhibition is from a point of However, because many novel agents target molecules that are only to tumor the inhibition of these target molecules has not yet to be of target inhibition in tumor are a more relevant end point for phase I trials where dosing is the is a that such as 18 to in function and can early when there is corresponding evidence of clinical ( ). changes in that from effective cytostatic when a response is not This is but to be can only tumor this test is not an to (i.e., the of disease in the 8 of and have a response of is something that the National Cancer of is as a means of identifying active agents in phase II In a of the phase II agents identified as “ they a response phase II decision the agents that have selected because they less than a maximum of is, the response have the of active Although this to be with and with disease for a new drug. and cannot be used for because there is evidence that, with changes in there may be in the over time. response can be in on the of cancer and the of has used as an end point in the of with cancer ( ) and in the trial of with cancer ( ). may be used to the response and may be of more in randomized studies of new approach to agents to cause tumor be to the traditional phase II screening process and proceed to phase III Preclinical such a development must be to the of time and that this approach The selected tumor must be there must be some for that the novel agent be effective in a particular disease because of the of the targeted should be in to trials early for therapies or if toxic effects are which phase I trials some from phase I that the new drug is the activity of the target or is biologic toxic changes to effective doses be At this therefore, the in phase II end points that could identify cytostatic drugs to survival, end can be of end points through their use in the selection of drugs that are to be effective in phase III trials will time. This time will be well if we can the need to novel cytostatic agent to evaluation in large randomized we have therapies as with an of and However, should these be applied to agents that may not the of cytotoxic compounds and may require there that we can learn from oncology that can be applied to the evaluation of our novel agents? The of anticancer has a response has a necessary and have used as less of activity in relatively As new therapies clinical trials, it is to the of is still a and ideal when However, for of disease with or toxicity be as a major it could also be to of if such an effect could be with This cytostatic as disease has many in oncology. are for for and for clinical evaluation of in disease ( ). ( ) a trial by use of an The of the of to of of with 2 The dose for was as 1) at or or 2) at or or 3) at or with evidence of from in the In the there was a and to a or to their dose or from the In the final all the dose of that their The concept of before is because it for are may have low for or are to the drug. The end point of this was in the during the was to be better than because there was a in the for in the was not to the disease process, only to has a disease without effective was selected for evaluation in this disease because of effects on to be in the of ( ). ( ) a trial in that was enhanced by the of with and with The end points and in and and clinical The major was that of was in the the for not cause disease but The use of in has controversial for years ( ). The and ( ) evaluated in in a in the of was by to any other for the The end points used criteria. The was 2 The in the based on the index or the of with new there was of the only a reduction in These trials of drugs for and that can potentially be applied to the development of cytostatic The point is that phase II trials can be randomized trials, ideally an agent and a A potential end point of such studies is delay of disease which may require a of analysis to disease is often used in trials but has not used in phase II trial designs or more active as well as a and in disease over a may be more efficient in phase II The the potential of which can before are to A particularly design for oncology trials may be the randomized where all of the can active before being to ( ). In this all the drug. At the end of an initial evaluation with disease or toxicity are from the and the are to continue or to ideally with a novel phase II trial designs will be which may the critical for development of these new This will require a major in the of and a years it that oncology to a with a of new now have a large of therapies in development and entering the clinical Many of these agents target signal transduction molecules and the cancer cell international consensus is to acceptable end points for targeted to activity or novel that may not our current therapies may and may in not by laboratory experiments or by new This will require approaches, and of our drug development programs that novel therapies are not for human trials of targeted agents for human trials of targeted agents for the development of targeted at testing and to clinical and the other of the 10th Symposium on New
No takes yet. Share an insight, caveat, or question.
Gelmon et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: